OCD drug candidate created by AI ready for clinical trials in record time
A new drug candidate has been created by artificial intelligence (AI) for the very first time, with the exploratory research route to phase I clinical trials taking less than 12 months, considerably shorter than the typical four and a half years using conventional research techniques.
DSP-1181 was developed by Japanese firm Sumitomo Dainippon Pharma in partnership with UK-based AI start-up Exscientia and is being progressed as a long-acting and potent serotonin 5-HT1A receptor agonist for the treatment of obsessive-compulsive disorder (OCD).
“We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery,” said Andrew Hopkins, CEO of Exscientia. “This project’s rapid success was through strong alignment of the integrated knowledge and experiences in chemistry and pharmacology on monoamine GPCR drug discovery at Sumitomo Dainippon Pharma with our AI technologies.”
“We are very excited with the results of the joint research that resulted in the development of candidate compounds in a very short time,” said Toru Kimura, Senior Executive Research Director at Sumitomo Dainippon Pharma. “We will continue to work hard to make this clinical study a success so that it may deliver new benefits to patients as soon as possible.”
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance